BiomarkersHumans
Plausibility of early and short acquisition windows for ¹⁸ F‐NAV4694 and ¹⁸ F‐florbetapir PET to expand clinical throughput
AAIC 2025 Abstract
Abstract
Background: Monoclonal antibody treatments may lead to increased demand for diagnostic Aβ PET. Simultaneously, high costs and limited reimbursement are pushing clinicians to alternatives such as plasma biomarkers, despite their inability to quantify amyloid burden.
The paper
Ashley Gillman, Pierrick Bourgeat, Jürgen Fripp, Christopher C. Rowe
Show 7 more authors
Victor L. Villemagne, Graeme Joseph O'Keefe, Kun Huang, Tammie L.S. Benzinger, Pamela LaMontagne, John C. Morris, Vincent Doré,Commonwealth Scientific and Industrial Research Organisation · The University of Melbourne
AAIC 2025 Abstract · 24 Dec 2025 · CC BY
Presented at AAIC 2025
